1/5
10:30 am
ctor
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR)
Neutral
Report
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR)
12/23
05:16 pm
ctor
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
12/23
04:30 pm
ctor
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Medium
Report
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
12/10
04:59 pm
ctor
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]
Low
Report
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]
12/10
04:30 pm
ctor
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Low
Report
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
12/9
08:30 am
ctor
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
High
Report
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
12/4
08:37 am
ctor
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
Low
Report
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
12/1
01:16 pm
ctor
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) [Yahoo! Finance]
Low
Report
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) [Yahoo! Finance]
12/1
12:00 pm
ctor
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
Low
Report
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
11/25
07:03 pm
ctor
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]
Medium
Report
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]
11/25
08:00 am
ctor
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
High
Report
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
11/21
08:48 am
ctor
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration [Yahoo! Finance]
High
Report
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration [Yahoo! Finance]
11/21
08:37 am
ctor
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
Medium
Report
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
11/20
01:33 pm
ctor
Citius Oncology (NASDAQ:CTOR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Citius Oncology (NASDAQ:CTOR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
05:27 am
ctor
When Will Citius Oncology, Inc. (NASDAQ:CTOR) Become Profitable? [Yahoo! Finance]
High
Report
When Will Citius Oncology, Inc. (NASDAQ:CTOR) Become Profitable? [Yahoo! Finance]